[print friendly]

pioglitazone (ACTOS)

• pioglitazone (ACTOS); rosiglitazone (AVANDIA)
  We list these drugs as Do Not Use drugs because they may be less effective than other drugs for diabetes and cause liver damage, weight gain, anemia and heart failure.

• Diabetes Prevention and Treatment [hide all summaries]
  Diets that are very complicated or very different from what you are used to are hard to follow. The American Diabetes Association (ADA) diet is a highly structured plan based on exchange lists. Although it serves its purpose of regulating calorie and sugar intake quite well, the ADA diet may be difficult for older people to use. Successful use of this diet requires considerable time spent planning meal patterns and food portions. Older people often have trouble with this diet because the food lists are long and complicated and require considerable memorization.

• A Review of Exenatide (BYETTA) for Type-2 Diabetes [hide all summaries]
  (November 2009)
  Because exenatide (BYETTA) is a new drug with increasing reports of severe, hospitalization-requiring pancreatitis and offers no significant breakthrough compared to other diabetes drugs, we urge readers not to use it until 2012--seven years after its approval, by which time much more will be known about its dangers.
• Public Citizen Urges Immediate Ban of Rosiglitazone (AVANDIA) [hide all summaries]
  (December 2008)
  On Oct. 30, Public Citizen formally petitioned the Food and Drug Administration (FDA) to immediately ban the dangerous diabetes drug rosiglitazone (AVANDIA) because the drug causes multiple types of serious toxicity.
• FDA: Women Taking AVANDIA, ACTOS at Increased Risk of Fractures [hide all summaries]
  (July 2007)
  Yet another reason has arisen to support our several years-old warning not to use the diabetes drugs AVANDIA or ACTOS. Randomized trials of both drugs, compared to other diabetes drugs, showed an increase in fractures in women (not men) using them.
• New Findings: AVANDIA Poses Risks of Heart Attacks, Heart Failure [hide all summaries]
  (July 2007)
  In addition to years-old information about increased heart failure in patients using AVANDIA, that Worst Pills readers have been warned about for years, new evidence has emerged about increased heart attacks as well. The article reviews the evidence for both of these serious problems and why we continue to advise people not to use either AVANDIA or the related drug, ACTOS.
• Dangerous, Inappropriate Prescribing Of Diabetes Drugs Metformin (GLUCOPHAGE), Rosiglitazone (AVANDIA), And Pioglitazone (ACTOS) To Patients With Heart Failure [hide all summaries]
  (September 2003)
  Government-sponsored research published in the July 2, 2003 Journal of the American Medical Association found that the diabetes drugs metformin (GLUCOPHAGE), rosiglitazone (AVANDIA), and pioglitazone (ACTOS) were being prescribed inappropriately to patients with heart failure and that the inappropriate prescribing of these drugs has been increasing over time.

• FDA Knew of Avandia’s Dangers Nearly Five Years Ago, Memo Shows [hide all summaries]
  The Food and Drug Administration (FDA) knew nearly five years ago about the dangers associated with the diabetes drug Avandia, an internal FDA memo shows.
• Letter sent to the Lancet on availability of information on thiazolidinediones. (HRG Publication #1534) [hide all summaries]
  However, drug company websites are not the only, and certainly not the best, place to find unpublished data on drugs. Consulting readily available US governmental sources on the internet can lead to different conclusions regarding drug safety and efficacy. Using FDA data sources, we have just completed our own assessment of the thiazolinediones.
• Petition to the Food and Drug Administration requesting that it immediately require labeling for the diabetes drugs troglitazone (Rezulin), rosiglitazone (Avandia) and pioglitazone (Actos)(HRG Publication #1514) [hide all summaries]
  Class efficacy issues include the lack of efficacy compared to previously available drugs, sulfonylureas, and the deterioration of blood sugar levels when patients are switched from other oral anti-diabetic drugs to the glitazones. Safety issues include liver toxicity, effects on heart function, weight gain, edema, anemia, low blood pressure, elevated lipid levels, and possible changes in progesterone levels.

• Drug Recall for pioglitazone (ACTOS) reported in July 22, 2009 FDA Enforcement Report
• Drug Recall for pioglitazone (ACTOS) reported in July 22, 2009 FDA Enforcement Report
• Drug Recall for pioglitazone (ACTOS) reported in June 24, 2009 FDA Enforcement Report
• Drug Recall for pioglitazone (ACTOS) reported in June 17, 2009 FDA Enforcement Report

SHOW secondary search results for pioglitazone (ACTOS)